A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2041082
Abstract: Abstract Background/aims Originator-adalimumab, an established treatment for patients with Crohn’s disease (CD), showed no difference in efficacy or adverse events versus adalimumab biosimilar SB5 (SB5-adalimumab) over 10 weeks (W) of treatment. To understand the long-term… read more here.
Keywords: sb5; treatment; originator adalimumab; sb5 adalimumab ... See more keywords